Four complementary capabilities — antibody discovery, drug format, and GMP manufacturing — built on more than two decades of glycobiology research at our Taipei facility.
GlycoNex was founded in 2001 as a collaboration with the late Dr. Sen-itiroh Hakomori of The Biomembrane Institute, a member of the U.S. National Academy of Sciences whose laboratory established much of the modern foundation of tumor-associated carbohydrate antigen (TACA) biology. More than two decades of focused work on TACAs at GlycoNex's Taipei facility have produced four complementary capabilities that together span the full development chain from antibody discovery to GMP clinical supply.
The GlycoSH antibody bank, accumulated continuously since the company's founding, supplies the antibody starting material for two distinct drug formats: glycan-targeted antibody-drug conjugates (ADCs) and pro-antibodies activatable in the tumor microenvironment. Both formats exploit a fundamental biological asymmetry — many carbohydrate antigens overexpressed on cancer cells are minimally present on healthy human tissue, offering a tumor-selectivity advantage not available to most protein-targeted approaches.
This approach reached the clinic in April 2026, when Japan's Pharmaceuticals and Medical Devices Agency (PMDA) cleared lead candidate GNX1021 for first-in-human Phase 1 trials in patients with gastrointestinal cancers.
GlycoNex's proprietary collection of monoclonal antibodies targeting tumor-associated carbohydrate antigens. Accumulated continuously since 2001, the bank supplies the antibody starting material for both the ADC and pro-antibody pipelines, and is available for collaborative discovery programs.
Antibody-drug conjugates that target carbohydrate antigens rather than proteins, exploiting tumor selectivity unavailable to most protein-targeted approaches. GlycoSH-derived antibodies are paired with clinically validated linker technology, with GNX1021 as the lead clinical candidate.
Antibody lock technology that holds the antibody dormant in circulation and selectively activates in the tumor microenvironment. In-licensed from Precisemab in May 2024, it underpins GNX201-ADC, co-developed with Nippon Kayaku since March 2026.
In-house GMP-compliant antibody production supporting Phase 1 clinical supply from GlycoNex's New Taipei facility. Used internally for the company's pipeline and offered externally as CDMO services — recent partners include Change Cure (2025) alongside long-term collaborators Sterling Pharma and EirGenix.
Glycobiology and oncology publications spanning more than two decades, including foundational work in collaboration with the late Dr. Sen-itiroh Hakomori and ongoing translational research with Hokkaido University Hospital.
View publications →Recent presentations include AACR 2025 (preclinical data on GNX1021), the J.P. Morgan Healthcare Conference Biotech Showcase 2025, and ongoing engagement with international oncology and biosimilar communities.
View presentations →Japan PMDA Phase 1 clearance for GNX1021 (April 2026). Taiwan IND submission for GNX1021 anticipated June 2026. SPD8 Phase 3 enrollment complete (October 2025), top-line data expected Q2 2026.
View pipeline →36 granted patents across multiple jurisdictions, spanning the GNX1021 / GNX102 antibody family and the licensed GNX8 program, with further applications published and pending. These filings cover glycan-directed antibody compositions and their therapeutic applications, built on two decades of glycobiology.
View patent portfolio →GlycoNex welcomes inquiries about research partnerships, technology licensing, and CDMO arrangements across all four capabilities.
Explore Partnership Opportunities →